I lead Digital Health for BioPharmaceuticals R&D. In Digital Health R&D, we are transforming R&D through digital, data and AI to deliver new digital health solutions to improve outcomes and experience for patients, and to partner with colleagues globally to reimagine healthcare delivery.
I lead a diverse team focusing on accelerating and differentiating our clinical development programmes through digital health solutions and on the development of digital therapeutics. A recent example is the implementation and scale up of Unify, our new clinical study support platform which is now part of several of our trials around the world. Unify is enabling us to improve remote patient data collection, as well as supporting clinical trial accessibility, diversity and retention. We also work actively with the R&D therapy area teams to explore approaches that can combine our innovative new treatments with evidence-based digital health solutions, such as digital biomarkers, digital diagnostics and digital therapeutics.
A chemist by training, I have been part of the pharmaceutical industry for over 25 years. I have been at AstraZeneca for over 20 years in various roles across R&D and Operations, including as Founder and Head of the Intelligent Pharmaceuticals group, Project Director in Chemistry, Manufacturing and Controls (CMC) and Project Lead roles across different therapy areas.
Throughout my time at AstraZeneca, I’ve been passionate about clinical innovation. I firmly believe we are moving towards a future where digital solutions have the potential to robustly improve medication use, collect data directly from patients to support self-management, and improve clinical outcomes.
Drug Information Association (DIA) Global Annual Meeting 2021
Realizing the Value of Digital Biomarkers Across the Product Lifecycle
Clinical Trials Europe 2021
Decentralised trials. Does the hype meet reality
2015 – 2018
Founder and Head of the Intelligent Pharmaceuticals group, responsible for the successful delivery of over 45 testing programmes and helping establish the foundations for scaling the use of digital solutions to deliver patient centric trials and for developing digital therapeutics
Project Director in CMC across all therapy areas, leading successful delivery of a number of Phase 3 programmes and innovating in early phase programmes through the use of exploratory investigational new drugs
2011 – 2013
Project Lead for a Microbial Sciences (infection) portfolio, leading the team to assess development options linked to potential for commercial differentiation
Veeva ID: Z4-35299
Date of preparation: July 2021